M. Kawamura et al., EFFECTS OF TAK-029, A NOVEL GPIIB IIIA ANTAGONIST, ON ARTERIAL THROMBOSIS IN GUINEA-PIGS, DOGS AND MONKEYS/, Thrombosis research, 86(4), 1997, pp. 275-285
The antithrombotic and bleeding time (BT) prolonging effects of TAK-02
9, a novel GPIIb/IIIa antagonist, were examined in three arterial thro
mbosis models. In guinea pigs, TAK-029 at 30 mu g/kg (i.v.) inhibited
ADP-induced ex vivo platelet aggregation completely and prolonged BT t
o 4.5 times the control value 5 min after administration, and it preve
nted thrombotic occlusion in 2 out of 5 animals in a photochemically-i
nduced basilar thrombosis model. TAK-029 at 100 mu g/kg (i.v.) prolong
ed BT more than 9 times 5 min after administration, and it prevented t
hrombus formation for over 60 min. In dogs, TAK-029 at 30 mu g/kg (i.v
.) inhibited ADP-induced ex vivo platelet aggregation by 87% 5 min aft
er administration, and it prevented thrombotic occlusion in injured an
d stenosed coronary arteries for 22 min without prolonging the BT. TAK
-029 at 100 mu g/kg (i.v.) inhibited platelet aggregation completely a
nd prolonged BT 3.6 times 5 min after administration, and it prevented
thrombus formation for over 45 min. In monkeys, TAK-029 at 10 mu g/kg
(i.v.) inhibited ADP-induced ex vivo platelet aggregation by 84% and
prolonged BT 4.6 times 5 min after the administration, and it prevente
d thrombotic occlusion in injured and stenosed carotid arteries for 24
min. TAK-029 at 30 mu g/kg (i.v.) completely inhibited platelet aggre
gation and thrombus formation for over 60 min, and it prolonged BT mor
e than 7.3 times 60 min after administration. In conclusion, TAK-029 e
xerted potent antithrombotic effects with BT prolongation in three dif
ferent arterial thrombosis models. TAK-029 may be effective for the tr
eatment of various arterial thrombotic diseases. (C) 1997 Elsevier Sci
ence Ltd.